The USFDA grants permission for emergency use of the Novavax vaccine.

The Novavax covid-19 has received an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
For individuals 18 years of age and older, Novavax is a two dose preliminary series vaccination. SARS-CoV-2 spike protein and Matrix-M Adjuvant are both present in Novavax. To improve the immunological response, the adjuvant is added to the vaccine.
Potential hazards and advantages have been examined and are known.
The fourth Covid-19 vaccine to be made available in the United States does so using a different vaccination technology than the preceding three authorized vaccines.